Moderna's Revenue Warning Sends the Stock Into the Red for 2024

Key Takeaways Moderna lowered its full-year guidance as falling European demand and a difficult U.S. market limited sales of its COVID-19 vaccine. The company reported a second quarter loss and a 30% drop in revenue. The stock tumbled, dropping into negative territory for the year. Moderna (MRNA) shares plunged after the COVID-19 vaccine maker slashed its outlook on lower demand in Europe and a tough market in the U.S. The company now expects full-year product revenue of $3 billion to $3.5 billion, down fro ...